Stocktwits Top 25 Week 22

Our updated list of the market's top stocks.

Stocktwits Top 25 Week 22

Welcome to the Stocktwits Top 25 Newsletter for Week 22 of 2024!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. 

Here are the Stocktwits Top 25 Lists for Week 22:

P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

S&P 500
ST Top 25 S&P 500

The S&P 500 Top 25 list (-1.81%) underperformed the S&P 500 index (-0.51%).

There were 2 major changes to the list this week.

Check out how the momentum meter has performed vs. the S&P 500 index.

Elevate Your Trading Game 👀

Unleash your trading potential with our new Edge subscription plan—featuring unique social data, an ad-free experience, and more!

The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (-2.52%) underperformed the Nasdaq 100 index (-1.44%).

There were no major changes to the list this week.

The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+7.47%) outperformed the Russell 2000 index (+0.16%).

There were 3 major changes to the list this week.

Top Dawg Of The Week 🐶

The Top 25 lists' Top Dawg was Summit Therapeutics, which rallied 157.10%. 📈

The biotech company soared this week after a late-stage trial in patients with non-small cell lung cancer met its goal. 🎯

Ivonescimab patients showed “a statistically significant and clinically meaningful improvement” in progression-free survival compared with Merck & Co.’s blockbuster cancer treatment, Keytruda.

Despite the study being conducted in China, analysts remain optimistic that the results would translate well to Western populations and that the drug could also be used to treat other diseases. 💉

$SMMT is up 232.95% YTD.

Get In Touch

Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲

Help us deliver the best content possible by completing this brief survey. 📝

Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧

Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍

Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍

Join the conversation

or to participate.